← All Signals

🏥 FDA: Fresenius Kabi USA, LLC — Class II

healthcarebearishSource: FDA
90%Confidence
0Views
FDASource
2026-04-21Date

Summary

Yet another Fresenius Kabi recall for a 500mL sodium chloride bag underscores persistent sterility assurance failures. The frequency of these events suggests deep-rooted operational challenges that could impact long-term profitability.

Actionable: Consider reducing exposure to Fresenius Kabi stock until evidence of effective corrective actions and quality system overhauls emerges.

AI Confidence: 90%

Data Points

firmFresenius Kabi USA, LLC
classificationClass II
statusOngoing
distributionUS Nationwide , Alaska, and Puerto Rico.
product0.9% Sodium Chloride Injection, USP, (4,500 mg per 500 mL) (9 mg per mL) 500 mL in a 500 mL freeflex bag, Rx only, Fresenius Kabi USA, LLC ("Fresenius

Get Signals Instantly

Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.

Subscribe Now